This is a repository copy of *Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100 : results from SWITCH 2.*

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/150721/

Version: Published Version

**Article:**
Heller, S.R. orcid.org/0000-0002-2425-9565, DeVries, J.H., Wysham, C. et al. (3 more authors) (2019) *Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100 : results from SWITCH 2.* Diabetes, Obesity and Metabolism, 21 (7). pp. 1634-1641. ISSN 1462-8902

https://doi.org/10.1111/dom.13708

**Reuse**
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:
https://creativecommons.org/licenses/

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2

Simon R. Heller MD1 | J. Hans DeVries MD2 | Carol Wysham MD3 | Charlotte T. Hansen MD4 | Melissa V. Hansen PhD4 | Brian M. Frier MD5

Aim: This study aimed to investigate the safety of insulin degludec (degludec) in relation to age and risk of hypoglycaemia post hoc in individuals with type 2 diabetes (T2D) (SWITCH 2 trial).

Methods: In this crossover study, individuals with T2D who were at risk of hypoglycaemia were randomized to double-blind treatment with degludec or insulin glargine 100 units/mL (glargine U100) ± oral antidiabetic drugs. After 32 weeks, patients crossed over to the other treatment. Primary endpoint was number of overall severe (positively adjudicated) or glucose-confirmed (plasma glucose <56 mg/dL; 3.1 mmol/L) symptomatic hypoglycaemia events during the two 16-week maintenance periods.

Results: For individuals ≤65 (n = 450) and >65 (n = 270) years, baseline median (range) duration of diabetes was 12 (1–40) vs 15 (1–54) years, mean HbA1c was 7.7% vs 7.4% and mean estimated glomerular filtration rate was 87.0 vs 63.7 mL/min/1.73 m², respectively. No significant differences in HbA1c reduction were seen in individuals ≤65 or >65 years. During both maintenance periods, treatment with degludec lowered rates of hypoglycaemia (overall/nocturnal symptomatic) vs those with glargine U100 in individuals ≤65 (31% vs 43%) and >65 (30% vs 41%) years. With degludec and glargine U100, respectively, six vs nine severe hypoglycaemic events occurred in individuals ≤65 or >65 years. During both maintenance periods, treatment with degludec lowered rates of hypoglycaemia (overall/nocturnal symptomatic) vs those with glargine U100 in individuals ≤65 (31% vs 43%) and >65 (30% vs 41%) years. With degludec and glargine U100, respectively, six vs nine severe hypoglycaemic events occurred in individuals ≤65 years and four vs eight events occurred in those >65 years. Adverse event rates were 3.2 and 3.3 events/patient-year for individuals ≤65 years and were 3.5 and 4.1 events/patient-year for individuals >65 years with degludec and glargine U100, respectively.

Conclusion: Treatment with degludec was safe and effective, with a frequency of hypoglycaemia lower than that with glargine U100 in both younger and older individuals (>65 years) with T2D.

Keywords: basal insulin, diabetes treatment, elderly, hypoglycaemia, type 2 diabetes
1 | INTRODUCTION

Type 2 diabetes (T2D) is a chronic, progressive disease that frequently necessitates treatment with basal insulin to maintain adequate glycaemic control.\(^1\) In an ageing population with increasing longevity, the global burden of diabetes in individuals 65 years of age or older is projected to increase from 122.8 million in 2017 to 253.4 million in 2045.\(^3\)

Hypoglycaemia, primarily associated with diabetes therapies, particularly insulin, is common in T2D,\(^4\)\(^5\) and increases with age and longer duration of diabetes.\(^6\) Non-severe episodes are associated with increased utilization of healthcare services and loss of work time,\(^7\)\(^8\)\(^9\) as well as impairment of quality of life; prevention of these episodes is therefore important. Severe hypoglycaemia is of even greater concern, as it has been shown to be associated with increased risk of cardiovascular events and mortality.\(^10\)\(^11\) As with non-severe events, severe episodes can increase utilization of healthcare resources, with adverse economic consequences.\(^12\)

Delay in intensifying treatment with insulin for many individuals with T2D is common, with fear of hypoglycaemia among patients and healthcare providers an important contributing factor.\(^13\) The problem of clinical inertia may be magnified in the context of older individuals.\(^14\) Treatment delay could place older individuals at greater risk of the microvascular and macrovascular complications of diabetes, as they often have less organ reserve and more comorbid conditions than younger individuals.\(^15\)

Basal insulin analogues, now in widespread use, have advantages over human insulin in reducing the risk of hypoglycaemia because of better pharmacokinetic/pharmacodynamic (PK/PD) profiles.\(^16\) The basal insulin analogue insulin degludec (degludec) has a PK/PD profile with an ultra-long duration of action,\(^17\) and these PK/PD properties have been shown to be preserved in elderly individuals.\(^18\) In type 1 diabetes, degludec has a four-times lower PD variability than insulin glargine 100 units/mL (glargine U100) (AUC GIR\(_{0-24h,SS}\), Coefficient of variation, 20% vs 82%).\(^19\) The performance of degludec vs glargine U100 has been studied in a large clinical development programme in which degludec was associated with a lower rate of hypoglycaemia, with rate reductions of 17%–86%, compared with glargine U100.\(^20\) In a dedicated cardiovascular outcomes trial (DEVOTE), a statistically significant 40% lower rate of adjudicated severe hypoglycaemia was observed in individuals using degludec compared with those using glargine U100.\(^21\)

Most randomized trials of insulins include very few older individuals, a population that is heterogeneous with respect to prevalence and severity of comorbidity, frailty and overall health.\(^22\) Consequently, little information exists concerning the performance of basal insulin analogues in older individuals with diabetes, particularly with respect to hypoglycaemia. A pre-planned meta-analysis of seven trials comparing degludec and glargine U100 in older patients (≥65 years) indicated that degludec had a 24% lower rate of overall confirmed hypoglycaemia vs glargine U100, and a 36% lower rate of confirmed nocturnal hypoglycaemia.\(^23\) Secondary analysis of the DEVOTE trial, which compared degludec with glargine U100, showed that degludec was associated with a lower rate of hypoglycaemia than glargine U100, regardless of age.\(^24\) A post hoc analysis of data from the SWITCH 2 trial\(^25\) has been utilized in the present report to explore whether older (>65 years) individuals with T2D responded similarly to younger individuals, with respect to the definitions of hypoglycaemia used in the primary analysis and other safety parameters when comparing degludec with glargine U100.

2 | METHODS

The detailed design of the SWITCH 2 trial and results of the primary analysis have been published.\(^19\) Briefly, SWITCH 2 was a randomized, double-blind, treat-to-target, two-period crossover trial in which adults (≥18 years) with T2D currently undergoing treatment with basal insulin, with or without oral antidiabetic drugs, were randomized 1:1 to receive degludec (Novo Nordisk, Bagsvaerd, Denmark) once daily and glargine U100 (Sanofi, Paris, France) once daily, in a randomized sequence by period. Participants were also randomized 1:1 within each sequence to a morning dose, between awakening and breakfast, or an evening dose, between the main meal and bedtime. To maintain blinding, both insulins were administered using vial and syringe (100 U/mL, 10 mL vials). Each treatment sequence included a 16-week titration period and a 16-week maintenance period. Primary endpoint was the number of overall symptomatic hypoglycaemia (severe or blood glucose-confirmed [≤56 mg/dL [3.1 mmol/L]] events during the maintenance period).\(^19\) Other endpoints included the rate of nocturnal symptomatic hypoglycaemia events, severe or blood glucose-confirmed between 12:01 AM and 05:59 AM (both inclusive) and severe hypoglycaemia, also assessed during the maintenance period. An external, blinded committee positively adjudicated all severe events.

To reflect a broad population of individuals with T2D at risk for hypoglycaemia, inclusion criteria required that individuals must fulfil at least one of the following criteria: at least one severe episode based on American Diabetes Association criteria;\(^24\) a moderate degree of chronic renal failure (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m\(^2\);\(^2\) reduced awareness of hypoglycaemia; insulin use for more than five years; or experience of a hypoglycaemic event (symptoms and/or blood glucose ≤70 mg/dL (<3.9 mmol/L)] within the previous 12 weeks.

In this post hoc analysis, data from the primary trial\(^25\) were examined according to age category at baseline; the younger group comprised individuals 65 years of age or younger and the older group comprised individuals above 65 years of age. Statistical analysis was similar to that used in the primary trial. Briefly, a Poisson model with individuals as random effect, with treatment, period, sequence and dosing time as fixed effects, and with logarithm of the observation time as offset was used to estimate the rate ratio for each classification of hypoglycaemia during the maintenance period.\(^25\) Age group was added to the model as a fixed class variable to facilitate age comparisons pooled across treatments.
3 | RESULTS

3.1 | Participants

Among the original cohort, 450 (62.5%) participants were 65 years of age or younger and 270 (37.5%) were above 65 years of age (Table 1). Among younger participants, the distribution according to sex was similar (49.8% female); however, among older participants, there were fewer females than males (42.2% vs 57.8%). At baseline, younger participants tended to be heavier (mean body mass index, 32.8 [5.8] vs 31.2 [5.3] kg/m²), to have higher mean HbA1c (7.7% [1.1] vs 7.4% [1.0] [95% CI, 0.60; 3.17]; P = 0.0168). Among older participants, there were comparable for both treatments, ranging from 89% to 91%.

Mean fasting plasma glucose was also reduced from baseline in both age groups. However, the magnitude of decrement was greater for older compared with younger participants during both treatment periods (age contrast, older vs younger, period 1. −0.51 mmol/L [95% CI, −0.87; −0.15]; P = 0.0054; period 2, −0.56 mmol/L [95% CI, −1.02; −0.10]; P = 0.0168).

3.2 | Comparisons between age groups in the pooled population

The cumulative number of hypoglycaemic events, by age group, during the two 16-week maintenance periods is shown in Figure 1. No statistically significant difference in older vs younger participants was observed in the estimated risk of overall symptomatic hypoglycaemia (relative risk [RR], 1.05 [95% CI, 0.79; 1.40]; P = 0.73) or nocturnal symptomatic hypoglycaemia (RR, 0.93 [95% CI, 0.63; 1.36]; P = 0.70). Older participants tended to experience more severe hypoglycaemic events, although the difference was not statistically significant (RR, 1.38 [95% CI, 0.60; 3.17]; P = 0.45).

Mean basal insulin dose was statistically significantly higher for younger than for older participants throughout the trial (age contrast, older vs younger, −0.14 U/kg [95% CI, −0.21; −0.08]; P < 0.001 [period 1] and −0.21 U/kg [95% CI: −0.29; −0.12]; P < 0.0001 [period 2]) (Figure S1).

With respect to glycaemic control, both younger and older participants showed reductions from baseline in mean HbA1c; no statistically significant difference was found in change from baseline HbA1c between older and younger participants in treatment period 1 (age contrast, older vs younger, −0.01% [95% CI, −0.15; 0.13]; P = 0.91) or in treatment period 2, −0.05% [95% CI: −0.18; 0.08]; P = 0.45).}

3.3 | Comparisons by treatment within age group

The observed rate of severe or blood glucose (BG)-confirmed symptomatic hypoglycaemia was lower for degludec compared with glargine U100 in older as well as in younger participants during the maintenance period (younger group, 184 vs 263 events/100 patient-years of exposure [PYE] for degludec and glargine U100, respectively; older group, 188 vs 269 events/100 PYE for degludec and glargine U100, respectively) (Table 2), with an estimated 31% and 30% lower rates of severe or BG-confirmed symptomatic hypoglycaemic events with degludec compared with glargine U100, in the younger group (treatment ratio, degludec:glargine U100, 0.69 [95% CI, 0.58; 0.83]; P < 0.0001) and in the older group (treatment ratio, degludec:glargine U100, 0.70 [95% CI, 0.56; 0.88]; P = 0.0023), respectively (Figure 2).

Treatment with degludec was also associated with an estimated 43% and 41% lower rates of nocturnal symptomatic hypoglycaemia than rates with glargine U100, in the younger group (treatment ratio, degludec:glargine U100, 0.57 [95% CI, 0.42; 0.78]; P = 0.0005) and in the older group (treatment ratio, degludec:glargine U100, 0.59 [95% CI, 0.39; 0.89]; P = 0.0117), respectively (Figure 2). The number of severe events was low in both the younger group (six with degludec and nine with glargine U100) and the older group (four with degludec and eight with glargine U100), and the risk of severe hypoglycaemia was not statistically significantly different for either younger (treatment ratio, degludec:glargine U100, 0.52 [95% CI, 0.15; 1.89]; P = 0.32) or older (treatment ratio, degludec:glargine U100, 0.63 [95% CI: 0.13; 2.98]; P = 0.56) participants by treatment.

HbA1c decreased with both treatments during the first 16-week titration period, after which values plateaued (Figure S2). No statistically significant difference was seen between treatments in either age group (degludec:glargine U100, 0.16% [95% CI, −0.02; 0.35]; P = 0.07 and −0.05% [95% CI, −0.26; 0.15]; P = 0.60) for younger and older participants, respectively. FPG decreased from baseline during the first 32-week treatment period for both treatments, after which FPG remained relatively stable across both treatments (Figure S3).

3.4 | Adverse events

Over the entire trial, in the safety analysis set, 307 of 444 (69.2%) younger patients and 194 of 269 (72.2%) older patients reported adverse events (AEs). The percentage of younger patients reporting AEs was almost identical for degludec and glargine U100 (57.5% and 57.8%, respectively). However, for older patients, a smaller proportion reported AEs with degludec (56.9% vs 66.7% for degludec vs glargine U100, respectively).
Serious AEs by preferred term and system organ class occurring ≥5% in either treatment arm for both age groups are listed in Table S1. These were mostly upper respiratory in nature. There were seven fatal events in total: two in patients treated with degludec (none in the younger group; one associated with sudden cardiovascular death and one caused by stroke in the older group) and five in patients treated with glargine U100 (one secondary to acute myocardial infarction and one caused by sepsis in the younger group; two associated with malignancy and one caused by sepsis in the older group).

### TABLE 1  Baseline characteristics, by age group

| Characteristic | ≤65 years (n = 450) | >65 years (n = 270) |
|---------------|---------------------|---------------------|
| Age (years) median [range] | 56.6 [20.9;65.0] | 71.5 [65.1;89.2] |
| Sex (n, %) | | |
| Female | 224 (49.8) | 114 (42.2) |
| Male | 226 (50.2) | 156 (57.8) |
| Ethnicity (n, %) | | |
| Hispanic or Latino | 175 (38.9) | 87 (32.2) |
| Not Hispanic or Latino | 275 (61.1) | 183 (67.8) |
| Body weight (kg) | 93.8 (20.3) | 88.3 (17.6) |
| BMI (kg/m$^2$) | 32.8 (5.8) | 31.2 (5.3) |
| Duration of diabetes (years), median [range] | 12 [1–40] | 15 [1–54] |
| Exposure to insulin >5 years (n, %) | 214 (47.6) | 142 (52.6) |
| Experience of at least one severe hypoglycaemic event during the previous year$^a$ (n, %) | 79 (17.6) | 39 (14.4) |
| Impaired awareness of hypoglycaemia$^b$ (n, %) | 81 (18.0) | 48 (17.8) |
| Experience of at least one hypoglycaemic event$^c$ within 12 weeks prior to visit 1 (screening) (n, %) | 298 (66.2) | 180 (66.7) |
| eGFR (mL/min/1.73 m$^2$) | 87.0 (18.9) | 63.7 (16.8) |
| Moderate chronic renal failure$^d$ (n, %) | 49 (10.9) | 110 (40.7) |
| Smoking status (n, %) | | |
| Never smoked | 230 (51.1) | 134 (49.6) |
| Previous smoker | 130 (28.9) | 115 (42.6) |
| Current smoker | 90 (20.0) | 21 (7.8) |
| HbA1c (%) | 7.7 (1.1) | 7.4 (1.0) |
| HbA1c (mmol/mol) | 60.3 (12.2) | 57.9 (11.2) |
| FPG (mmol/L) | 7.8 (2.9) | 7.2 (2.9) |
| FPG (mg/dL) | 140.9 (52.9) | 130.6 (51.4) |

**Note.** All values are mean (SD) unless otherwise specified.

**Abbreviations:** BMI, body mass index; CKD-EPI, chronic kidney disease epidemiology collaboration; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; n, number of subjects; SD, standard deviation.

$^a$Event requiring assistance of another person to actively administer carbohydrate or glucagon, or to take other corrective action. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence.

$^b$History of impaired autonomic responses (tremulousness, sweating, palpitations and hunger) during hypoglycaemia.

$^c$Defined by symptoms of hypoglycaemia and/or event with low glucose measurement (≤70 mg/dL [≤3.9 mmol/L]).

$^d$Glomerular filtration rate 30–59 mL/min/1.73 m$^2$ per CKD-EPI by central laboratory analysis.

### DISCUSSION

Results of the randomized, double-blind, crossover trial, SWITCH 2, were examined to assess the effect of age on hypoglycaemia risk, comparing degludec with glargine U100. The SWITCH 2 trial was powered to evaluate the superiority of degludec vs glargine U100 with respect to overall symptomatic hypoglycaemia. During the maintenance period, treatment with degludec was associated with statistically significantly lower rates
of severe and symptomatic hypoglycaemic events (BG-confirmed) compared with glargine U100, with a 31% reduction in younger patients (≤65 years) and a 30% reduction in older patients (>65 years). Concerning nocturnal symptomatic hypoglycaemia, the reduction in rates were 43% and 41%, respectively, for these age groups. These treatment differences were comparable between age groups, and this lower rate was similar to the 27% lower rate of overall confirmed hypoglycaemia (estimated rate ratio, degludec:glargine U100, 0.73 [95% CI, 0.56; 0.96]) and the 39% lower rate in nocturnal hypoglycaemia (estimated rate ratio, degludec:glargine U100, 0.61 [95% CI, 0.37; 1.03]) during the maintenance period reported in a pre-planned meta-analysis of seven phase IIIa open-label trials in individuals aged at least 65 years of age, comparing degludec and glargine U100 in T2D.24 In contrast to the SWITCH 2 trial, the core trials in the meta-analysis were powered to detect differences in HbA1c. Nevertheless, these similarly lower rates across trials with heterogeneous patient populations, ranging from insulin-naïve to basal-bolus users, with or without an increased risk of hypoglycaemia at baseline, support the overall benefit of treatment with degludec compared with glargine U100.

The number of severe hypoglycaemic events reported in the present analysis were not statistically different by treatment for either age group, probably because the overall number of events was very low. As this was a treat-to-target trial, as expected, no treatment differences were observed in change in HbA1c from baseline in either the older or the younger participants. Younger individuals required a higher mean insulin dose (U/kg) compared with older individuals throughout the trial, which may have been related to greater insulin resistance, in line with the tendency of a higher body mass index among younger individuals.

Older individuals with T2D are generally at increased risk of, and more vulnerable to, hypoglycaemia than younger individuals, for several reasons, including impaired renal function,26 reduced ability to recognize and respond to hypoglycaemia,27 and altered physiological responses to low glucose levels.28 Symptoms of hypoglycaemia become less intense and their symptom profile changes with increasing age,25 with symptomatic responses manifesting only at BG levels lower than those in younger individuals, leaving less time to recognize and respond to them.20,31 Thus, when hypoglycaemia develops in an older individual with T2D, it might not be identified or reported, which may explain the absence of a significantly higher rate of overall hypoglycaemia in older individuals, as was observed in the present study.

Reduced awareness of hypoglycaemia with advancing age may increase the risk that an event progresses in severity and results in more severe events in the older age group. There was a numerically greater rate of severe hypoglycaemia in older individuals compared with younger individuals (RR, 1.38) in the current trial, although the trend was not statistically significant. Severe hypoglycaemia is generally much more common in real-world populations than in randomized clinical trials.4,5,32 In addition, continuous glucose monitoring has demonstrated that many episodes are unrecognized and under-reported.33 Furthermore, it has been estimated that only 5% of self-reported severe hypoglycaemia events among individuals with diabetes who are undergoing pharmacological treatment are captured by traditional healthcare utilization-based surveillance systems, suggesting a substantial underestimate of the true burden.34 This may be related, at least in part, to the low number of episodes of severe hypoglycaemia in both age groups (15 events in 11/413 younger individuals and 12 events in 11/240 older individuals) (Table 2). Baseline characteristics that could have influenced the risk of hypoglycaemia were not markedly different between younger and older individuals, with the
exception of an almost four-fold greater prevalence of chronic moderate renal failure in older individuals (40.7% vs 10.9%) (Table 1).

Multiple comorbidities, polypharmacy and increased use of concomitant medications in older individuals with T2D may increase the risk of hypoglycaemia, and insulin metabolism may alter with age.\textsuperscript{35} In particular, a greater prevalence and severity of renal insufficiency in older individuals and a greater frequency of visual and/or cognitive impairment may interfere with routine self-care in individuals with diabetes.\textsuperscript{22,36,37} Frailty\textsuperscript{37} can compound the burden of self-management in older individuals and increase hypoglycaemia risk. Living alone may also increase vulnerability, as external assistance to treat severe hypoglycaemia is difficult or impossible to engage. It may also contribute, in part, to failure to identify hypoglycaemic events, and may lead to an underestimation of severe events in older individuals with T2D. The morbidity associated with hypoglycaemia may be more common and severe in older individuals. This includes a greater risk of falls and injuries such as fractures, which occur more frequently with advancing age.\textsuperscript{36}

An important limitation of the present study is that the analysis of data from patients subdivided into age groups was not prespecified and was thus post hoc. Furthermore, information that would allow formal examination of the level of frailty in older individuals was not

| Type of hypoglycaemia           | ≤65 years (n = 413) | >65 years (n = 240) |
|---------------------------------|---------------------|---------------------|
|                                 | Insulin degludec   | Insulin glargine U100 | Total |
|                                 | N       | %       | E | R | N       | %       | E | R | N       | %       | E | R |
| Severe or BG-confirmed symptomatic | 85   | 21.4   | 220 | 184 | 118 | 30.3   | 310 | 263 | 156 | 37.8   | 530 | 223 |
| Nocturnal severe or BG-confirmed symptomatic | 39 | 9.8 | 64 | 53.6 | 61 | 15.7 | 109 | 92.57 | 81 | 19.6 | 173 | 72.95 |
| Severe                          | 6      | 1.5    | 6  | 5.02 | 8     | 2.1    | 9   | 7.64 | 11 | 2.7    | 15 | 6.33 |

Note. Values during the two 16-week maintenance periods.
Abbreviations: %, percentage of participants; BG, blood glucose; E, number of events; N, number of participants; R, rate (number of events divided by patient-years of exposure multiplied by 100).
were male; this may affect the generalizability of results to the older study, a larger percentage (57.8%) of individuals in the older age group collected. It would have been valuable to assess whether frail patients 1640 HELLS were at similar risk of overall symptomatic hypoglycaemia or nocturnal symptomatic hypoglycaemia, but older patients showed a tendency toward higher risk of severe hypoglycaemia. Treatment with degludec led to similar reductions in HbA1c and a similar adverse-event profile, with a lower risk of hypoglycaemia than treatment with glargine U100, both in older and younger individuals with T2D.

ACKNOWLEDGEMENTS

Medical writing and submission support were provided by Gary Patronek and Helen Marshall of Watermeadow Medical, an Ashfield company, part of UDG Healthcare plc, and were funded by Novo Nordisk. We also thank Thomas Mark, Novo Nordisk, Søborg, Denmark, for his review of and input to the manuscript.

Subject-level analysis data sets for the research presented in the publication are available from the corresponding author upon reasonable request.

CONFLICT OF INTEREST

S. R. H. has participated in advisory panels for Eli Lilly and Company, Novo Nordisk A/S, Takeda, Sanofi-Aventis and Boehringer Ingelheim GmbH; has been a consultant to Eli Lilly and Company and Novo Nordisk A/S; and has participated in speakers’ bureaus for Novo Nordisk A/S, Eli Lilly and Company, Merck Sharp & Dohme Corp., Takeda, AstraZeneca and Boehringer Ingelheim GmbH.

J. H. D. has received research support from Dexcom, Inc., Medtronic, Novo Nordisk A/S and Senseonics; has participated in advisory panels for Novo Nordisk A/S, Sanofi and Zealand Pharma A/S; and has participated in speakers’ bureaus for Novo Nordisk A/S, Roche Diabetes Care Health and Digital Solutions and Senseonics.

C. H. W. has participated in advisory panels for Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals Inc. and Sanofi; has been a consultant to AstraZeneca, Janssen Pharmaceuticals Inc., Novo Nordisk Inc. and Sanofi; and has participated in speakers’ bureaus for AstraZeneca, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly and Company, Janssen Pharmaceuticals Inc., Insulet Corporation, Novo Nordisk Inc. and Sanofi.

C. T. H. and M. V. H. are employees of and hold stock in Novo Nordisk.

BMF has participated in advisory panels for Novo Nordisk A/S and Eli Lilly and Company; has been a consultant to Locemia Solutions and Zucara Therapeutics; and has participated in speakers’ bureaus for Novo Nordisk A/S, Eli Lilly and Company, Roche Pharma and AstraZeneca.

AUTHOR CONTRIBUTIONS

S. R. H., J. H. D., C. W., C. T. H., M. V. H. and B. M. F. contributed to the study design. S. R. H., J. H. D., C. W. and C. T. H. contributed to study conduct and data collection. S. R. H., J. H. D., C. W., C. T. H., M. V. H. and B. M. F. contributed to analysis of the data. S. R. H., J. H. D., C. W., C. T. H., M. V. H. and B. M. F. wrote the manuscript. Novo Nordisk contributed to the study design, statistical analyses, data interpretation, manuscript preparation and the decision to submit this manuscript for publication. All of the authors had access to study data and took full responsibility for the content of the manuscript and the decision to submit it for publication.

ORCID

Simon R. Heller https://orcid.org/0000-0002-2425-9565
J. Hans DeVries https://orcid.org/0000-0001-9196-9906
Carol Wysham https://orcid.org/0000-0002-3056-0047

REFERENCES

1. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669-2701.
2. American Diabetes Association. Older adults. Sec. 10. In Standards of Medical Care in Diabetes 2015. Diabetes Care. 2015;38(suppl. 1): S67-S69.
3. International Diabetes Federation. IDF Diabetes Atlas – 8th Edition. Available at: http://diabetesatlas.org/resources/2017-atlas.html. 2017. Accessed November 2018.
4. Khunti K, Al-Sifri S, Aronson R, et al. HAT Investigator Group. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18:907-915.
5. Ratziu-Leewing A, Harris SB, Mequanint S, et al. Real-world crude incidence of hypoglycaemia in adults with diabetes: results of the InHypo-DM study. Canada. BMJ Open Diabetes Res Care. 2018;6:e000503.
6. Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med. 2014;174: 251-258.
7. Brod M, Wolden M, Groeleau D, Bushnell DM. Understanding the economic, daily functioning, and diabetes management burden of non-
severe nocturnal hypoglycemic events in Canada: differences between type 1 and type 2. J Med Econ. 2014;17:11-20.
8. Frier BM, Jensen MM, Chubb BD. Hypoglycaemia in adults with insulin-treated diabetes in the UK: self-reported frequency and effects. Diabet Med. 2016;33:1125-1132.
9. Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weigtasser R, Lahtela J, Jensen MM, Ostenson CG. Effects of patient-reported non-severe hypoglycaemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. J Med Econ. 2013;14:1453-1461.
10. Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardio-vascular outcomes and mortality. Diabetologia. 2018;61:58-65.
11. Seagquist ER, Anderson J, Childs B, et al. Hypoglycaemia and diabetes: a report of a workshop of the American Diabetes Association and the Endocrine Society, Diabetes Care. 2013;36: 1384-1395.
12. Heller SR, Frier BM, Herslavl ML, Gundgaard J, Gough SC. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med. 2016;33:471-477.
13. Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20:488-496.
14. Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18:401-409.
15. Corriere M, Rooparinesingh N, Kalyani RR. Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health burden. Curr Diab Rep. 2013;13:805-813.
16. Frier BM, Russell-Jones D, Heise T. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes Metab. 2013;15: 978-986.
17. Heise T, Korsatko S, Nosek L, et al. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. J Diabetes. 2016;8:132-138.
18. Korsatko S, Deller S, Mader JK, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Drugs Aging. 2014;31: 47-53.
19. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr M. Insulin deglucde: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859-864.
20. Ratner R, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175-184.
21. Marso SP, McGuire DK, Zimman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377: 729-732.
22. Kirkman MS, Briscoe VJ, Clark N, et al. Consensus development conference on diabetes and older adults. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60:2342-2346.
23. Sorli C, Warren M, Oyer D, Mersebach H, Johansen T, Gough SC. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging. 2013;30: 1009-1118.
24. Pratley RE, Emerson S, Frank E, et al. Cardiovascular (CV) safety and severe hypoglycaemia benefit of insulin degludec versus insulin glargine U100 in older patients (≥65 years) with type 2 diabetes (T2D): observations from DEVOTE. Diabetes. 2018;67(suppl 1):A28 (abstract 108-OR).
25. Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec versus insulin glargine U100 on hypoglycaemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318: 45-56.
26. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycaemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4: 1121-1127.
27. Bremer JP, Jauch-Chaara K, Hallsmidm S, Schmid S, Schultes B. Hypoglycaemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513-1517.
28. Sircar M, Bhatia A, Munshi M. Review of hypoglycaemia in the older adult: clinical implications and management. Can J Diabetes. 2016;40: 66-72.
29. Jaap AJ, Jones GC, McCrimmon RJ, Deary IJ, Frier BM. Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin. Diabet Med. 1998;15:398-401.
30. Matyka K, Evans M, Lomas J, Cranston I, Macdonald I, Amiel SA. Altered hierarchy of protective responses against severe hypoglycaemia in normal aging in healthy men. Diabetes Care. 1997;20: 135-141.
31. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycaemia in the elderly patient with diabetes. Diabetes. 1994;43:403-410.
32. Elliott L, Fidler C, Ditchfield A, Stissing T. Hypoglycaemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther. 2016;7: 45-60.
33. Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycaemia in type 2 diabetes – more common than you think: a continuous glucose monitoring study. J Diabetes Sci Technol. 2015;9: 999-1005.
34. Karter AJ, Moffett HH, Liu JY, Lipska KJ. Surveillance of hypoglycaemia--limitations of emergency department and hospital utilization data. JAMA Intern Med. 2018;178:987-988.
35. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycaemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157:1681-1686.
36. Abdelhafiz AH, Rodriguez-Mañas L, Morley JE, Sinclair AJ. Hypoglycaemia in older people - a less well recognized risk factor for frailty. Aging Dis. 2015;6:156-167.
37. Yanase T, Yanagita I, Muta K, Nawata H. Frailty in elderly diabetes patients. Endocr J. 2018;65:1-11.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Heller SR, DeVries JH, Wysham C, Hansen CT, Hansen MV, Frier BM. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2. Diabetes Obes Metab. 2019;21:1634–1641. https://doi.org/10.1111/dom.13708